Professor David Nutt discusses Awakn's PTSD therapeutics collaboration with Graft Polymer UK

Proactive - Interviews for investors

Awakn Life Sciences chief scientific officer Professor David Nutt speaks with Proactive's Stephen Gunnion about the company's new commercial collaboration with Graft Polymer UK. This partnership aims to advance Awakn's novel aminoindane new chemical entity (NCE) series, targeting trauma disorders such as PTSD, depression, and addictions. In the interview, Nutt highlighted the serious nature of PTSD, describing it as a "disorder of this century." He noted that current treatments are inadequate, and the collaboration seeks to enhance the bioavailability and pharmacokinetics of these new therapeutics. The partnership also includes a £300,000 investment from Graft Polymer UK to improve drug delivery systems. Nutt explained that the new technology could make treatment more efficient, reducing the time needed for therapeutic sessions, and improving patient outcomes. He emphasised the importance of finding better solutions for trauma-related disorders, particularly given the increasing prevalence of PTSD among populations affected by war and other traumatic events. To hear more about how Awakn Life Sciences and Graft Polymer UK are working together to revolutionise PTSD treatment, watch the full interview with Professor David Nutt. For more videos, visit Proactive's YouTube channel. Don’t forget to give the video a like, subscribe to the channel, and enable notifications for future content. #AwaknLifeSciences #PTSDTreatment #MentalHealth #DavidNutt #PharmaceuticalInnovation #GraftPolymer #TraumaTherapy #MentalHealthRevolution #NewDrugDevelopment #Bioavailability #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews